Navigation Links
Cempra, Inc. Reports Fourth Quarter and Full Year 2012 Financial and Operating Results
Date:2/28/2013

CHAPEL HILL, N.C., Feb. 28, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the fourth quarter and full year ended Dec. 31, 2012. The company will host a conference call and webcast at 4:30 p.m. EST, today.

"2012 was a transformational year for Cempra," said Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra. "We raised sufficient capital through our IPO and a subsequent private placement to advance our two differentiated antibiotics in clinical development.  Solithromycin is now in the first of two planned Phase 3 clinical trials in community-acquired bacterial pneumonia or CABP and Taksta (CEM-102) is undergoing a Phase 2 trial in patients with prosthetic joint infections or PJIs.  2013 will also be an important year as we expect to hold an end-of-Phase 2 meeting with the FDA during the first half of 2013 for solithromycin in CABP as the key step in preparing for the IV-to-oral second Phase 3 trial, which we expect to start in the second half of 2013 subject to available resources.  We also anticipate presenting some top-line results for the TAKSTA™ Phase 2 trial in PJIs in the fourth quarter of 2013."

Financial ResultsQuarter ended December 31, 2012 compared to quarter ended December 31, 2011

For the quarter ended December 31, 2012, Cempra reported a net loss of $6.6 million, or $0.26 per share, compared to a net loss of $3.8 million, or $7.13 per share, for the same period in 2011. 

Research and development expense in the quarter ended December 31, 2012, was $4.4 million, a 20
'/>"/>

SOURCE Cempra, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. United States Patent and Trademark Office to Require Signed NDA Affects Many Reports Wysebridge
2. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2013
3. Soligenix Reports Year-End 2012 Financial Results and Highlights Recent Accomplishments
4. InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
5. Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
6. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
7. Neuland Labs Reports Third Quarter Fiscal Year 2013 Financial Results
8. Intraocular Lens (IOL) Market Worth $3.8 Billion By 2018 Say New Research Report at ReportsnReports.com
9. Regenerative Medicine and Stem Cells Market Deals Analysis in New Research Report at ReportsnReports.com
10. Cellular Therapy Market and Cord Blood Market 2013 Industry Research Report: MarketResearchReports.Biz
11. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Research and ... "Global Enzyme for Pulp & Paper Industry Report 2014" ... Global Enzyme for Pulp & Paper Industry Report 2014 ... state of the global enzyme for pulp & paper ... of the industry including definitions, classifications, applications and industry ...
(Date:8/27/2014)... Florida (PRWEB) August 27, 2014 ... (SCI) is announcing the creation of the Sancilio ... to take the SCI’s philosophy of looking to ... research and development actions are based on sound ... new Scientific Advisory Board provides a vehicle for ...
(Date:8/27/2014)... College, PA (PRWEB) August 27, 2014 ... Simulation Software with new features for the biomedical ... is an enhanced Biological Thermal Sensor, exclusive to the ... a specialty version of XFdtd, developed to calculate the ... export functionality has been added to all versions to ...
(Date:8/26/2014)... ANGELES , Aug. 26, 2014  NeuroSigma, Inc., ... company established to develop bioelectronic technologies, today announced that ... with the U.S. Securities and Exchange Commission relating to ... The number of shares to be offered and the ... been determined. Jefferies LLC will act as ...
Breaking Biology Technology:Global Enzyme for Pulp & Paper Industry Report 2014 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 2Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 3
... 4, 2008 /PRNewswire/,-- Raven biotechnologies, inc., a privately ... monoclonal antibody therapeutics (MAbs) for,cancer, and the Bioprocessing ... the discovery of novel cancer stem cell,antibodies., ... license its proprietary,whole cell immunization technology for use ...
... 2008 Pharmasset,Inc. (Nasdaq: VRUS ) management will ... April 9, 2008 at the St. Regis Hotel,in New ... an overview of the company,s clinical and preclinical hepatitis ... access a simultaneous webcast of Mr. Price,s overview via ...
... EDT - ... consolidated net sales increased 21.2% year-over-year to ... $317.2 million, - Provided 2008 guidance: revenue of $360 million to $370 million; EBITDA ... of $28 million to $30 million, - Net beds served increased 21% year-over-year to 63,800 at ...
Cached Biology Technology:Raven biotechnologies and Bioprocessing Technology Institute Announce Collaboration to Advance Discovery of Stem Cell Antibodies 2Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th 2Chem Rx Corporation Reports Full Year 2007 Financial Results 2Chem Rx Corporation Reports Full Year 2007 Financial Results 3Chem Rx Corporation Reports Full Year 2007 Financial Results 4Chem Rx Corporation Reports Full Year 2007 Financial Results 5Chem Rx Corporation Reports Full Year 2007 Financial Results 6Chem Rx Corporation Reports Full Year 2007 Financial Results 7Chem Rx Corporation Reports Full Year 2007 Financial Results 8Chem Rx Corporation Reports Full Year 2007 Financial Results 9Chem Rx Corporation Reports Full Year 2007 Financial Results 10Chem Rx Corporation Reports Full Year 2007 Financial Results 11Chem Rx Corporation Reports Full Year 2007 Financial Results 12Chem Rx Corporation Reports Full Year 2007 Financial Results 13Chem Rx Corporation Reports Full Year 2007 Financial Results 14Chem Rx Corporation Reports Full Year 2007 Financial Results 15
(Date:8/27/2014)... belief that a deficiency in serotonin a chemical ... in depression. In the journal ACS Chemical Neuroscience ... make serotonin in their brains (and thus should have ... symptoms. , Donald Kuhn and colleagues at the ... University School of Medicine note that depression poses a ...
(Date:8/27/2014)... factors thought to be associated with outcomes after ... age of the patient, mechanism of injury, nerve ... method, operation technique, and repair materials. However, despite ... peripheral nerve injuries, there is no agreement regarding ... the dose-effect relationship of the predictors has not ...
(Date:8/27/2014)... State University have found that century-old museum specimens hold clues ... pest that can weaken and kill trees and the ... insect populations increase on oak and maple trees in warmer ... also increase with global warming," says Dr. Elsa Youngsteadt, a ... paper on the work. , "More scale insects would be ...
Breaking Biology News(10 mins):New study throws into question long-held belief about depression 2Museum specimens, modern cities show how an insect pest will respond to climate change 2
... Reportlinker.com announces that a new market research report is ... Forecast to 2012 - http://www.reportlinker.com/p096440/Global-Biometric-Forecast-to-2012.html ... the fastest emerging markets for the past few years ... and the advent of new technologies that offered numerous ...
... and "Invasive Alien Species in the Caribbean Basin of Concern ... will be presented at a joint meeting between the Southeastern ... Caribbean Division of the American Phytopathological Society (APS). The ... San Juan, March 19-22, 2011, as hundreds of entomologists and ...
... To the surprisingly inventive uses for banana peels ... of house plants scientists have added purification of ... which concludes that minced banana peel performs better than ... journal Industrial & Engineering Chemistry Research . ...
Cached Biology News:Reportlinker Adds Global Biometric Forecast to 2012 2CSI and alien invaders in Puerto Rico 2
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
ID clarifier: With ethidium bromide (50 μg/ml)...
... in DMEM and harvested at the log phase ... antigens in their native forms, cells were fixed ... a 12-well (5 mm) adhesive coated slide, with ... attachment and to minimize background staining. Each ...
Biology Products: